Removab (catumaxomab)

Catumaxomab is a trifunctional antibody intraperitoneal (IP) immunotherapy authorized in Europe that can be used to diminish malignant ascites by targeting EpCAM...This reaction was strengthened by anti-PD-L1 or anti-Gr1. When paired with CD137 co-stimulatory signaling, CAR-T cells for folate receptor cancers made it easier for T-cell tumors to find their way to and stay alive in the body.

Tx 50 μg 01-04 pTaG3Tis CAT pTis CR CR CR CR CR BCG 01-05 pTaG2Tis CAT CR CR pTaG2 recurrence CR pTaG2 recurrence decl. 01-06 pTaG3Tis CAT pTaG3Tis Tis pTaG3Tis recurrence CR CR BCG 70 μg 01-07 pTaG3 CAT CR CR CR CR BCG 01-08 pTaG3Tis CAT CR CR CR CR BCG 01-09 pT1G3Tis CAT CR CR CR CR 01-10 pT1G3TaG2 CAT CR CR CR 100 μg 01-12 pT1G3 CAT CR CR 01-13 pTaG3 CAT CR CR 02-01 pT1 CAT CR CR CAT, Catumaxomab; CR, complete remission; BCG, Bacille Calmuette Guerin; decl, declined

P1, N=30, Recruiting, Lindis Biotech GmbH | Trial primary completion date: Dec 2021 --> Dec 2022

Endoscopically confirmed recurrence-free intervals were 32 and 25 months. Our data suggest that intravesical administration of catumaxomab in NMIBC is feasible, safe and efficacious, thus arguing for further clinical development of catumaxomab in this indication.

P1, N=30, Recruiting, Lindis Biotech GmbH

In these GCT lines of variable EpCAM surface expression, targeting T cells by the prototypic bispecific EpCAM/CD3-antibody (bAb) Catumaxomab together with natural killer (NK) cell engagement via the Fc domain promotes profound cytotoxicity across a broad range of antibody dilutions...In the CHC line JAR, NK cell-dependent cytotoxicity dominates, which may be attributed to differential surface expression of immunomodulatory proteins such as MHC-I, CD24, and Fas receptors on CHC and EC. In view of redirecting T cell therapy mediated by bispecific antibodies, such differences in GCT immunophenotype potentially favoring immune escape are worth further investigation.